- Title
- Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
- Creators
- Bradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USAEmese Zsiros - Roswell Park Comprehensive Cancer CenterAlexandra Sebastianelli - CHU de Québec-Université LavalRadosław Mądry - Department of Gynecologic Oncology, Medical University Karol Marcinkowski, Poznań, PolandCarolina Ibañez - Pontificia Universidad Católica de ChileJacob Korach - Tel Aviv UniversityKosei Hasegawa - Saitama Medical UniversityFatih Kose - Başkent UniversityRoberto Ivan Romero Diaz - Centro de Investigacion Clinica de Oaxaca, Oaxaca de Juarez, MexicoEmma Hudson - Velindre Cancer Centreet al.
- Publication Details
- Gynecologic oncology, Vol.208, pp.S31-S31
- Publisher
- Elsevier Inc
- Identifiers
- 991006271509902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
Gynecologic oncology, Vol.208, pp.S31-S31
05/2026
Metrics
1 Record Views